Caribou Biosciences (CRBU) Assets (2020 - 2026)
Caribou Biosciences (CRBU) posted quarterly Assets of $149.0 million for Q1 2026, down 45.55% year-over-year from $273.7 million in Q1 2025, and down 15.04% quarter-over-quarter from $175.4 million in Q4 2025.
Caribou Biosciences (CRBU) Assets (2020 - 2026) Analysis & Trends
Caribou Biosciences (CRBU) has reported Assets for 7 consecutive years, with $149.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets fell 45.55% year-over-year to $149.0 million; the TTM figure through Mar 2026 stood at $149.0 million (down 45.55% YoY), while the FY2025 annual figure was $175.4 million, down 44.03% from the prior year.
- Assets slipped to $149.0 million in Q1 2026 per CRBU's latest filing, from $175.4 million in the prior quarter.
- Across five years, Assets topped out at $457.5 million in Q3 2023 and bottomed at $149.0 million in Q1 2026.
- Historically, Assets has averaged $334.0 million across 5 years, with a median of $349.6 million in 2023.
- Annual changes were most pronounced in 2022 — Assets jumped 166.02% — and 2026, when it slumped 45.55%.
- Caribou Biosciences' Assets stood at $373.8 million in 2022, then grew by 15.64% to $432.2 million in 2023, then declined by 27.51% to $313.3 million in 2024, then plunged by 44.03% to $175.4 million in 2025, then decreased by 15.04% to $149.0 million in 2026.
- Business Quant data shows CRBU's Assets at $149.0 million in Q1 2026, $175.4 million in Q4 2025, and $195.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.56 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.10 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.60 Bn |
| 10 | Caribou Biosciences | 163.09 Mn | 50.78 Mn | - | 142.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 142.77 Mn |
| Mar 31, 2026 | 149.00 Mn |
| Dec 31, 2025 | 175.37 Mn |
| Sep 30, 2025 | 194.98 Mn |
| Jun 30, 2025 | 220.90 Mn |
| Mar 31, 2025 | 273.66 Mn |
| Dec 31, 2024 | 313.31 Mn |
| Sep 30, 2024 | 344.33 Mn |
| Jun 30, 2024 | 372.94 Mn |
| Mar 31, 2024 | 406.83 Mn |
| Dec 31, 2023 | 432.21 Mn |
| Sep 30, 2023 | 457.52 Mn |
| Jun 30, 2023 | 349.65 Mn |
| Mar 31, 2023 | 347.46 Mn |
| Dec 31, 2022 | 373.77 Mn |
| Sep 30, 2022 | 398.82 Mn |
| Jun 30, 2022 | 421.37 Mn |
| Mar 31, 2022 | 446.00 Mn |
| Dec 31, 2021 | 442.36 Mn |
| Sep 30, 2021 | 461.96 Mn |